Cargando…
LPD-12: a promising lipopeptide to control COVID-19
INTRODUCTION: : The recent pandemic outbreak of SARS-CoV-2 has been associated with a lethal atypical pneumonia, making COVID-19 an urgent public health issue with an increasing rate of mortality and morbidity. There are currently no vaccines or therapeutics available for COVID-19, which is causing...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647407/ https://www.ncbi.nlm.nih.gov/pubmed/33166692 http://dx.doi.org/10.1016/j.ijantimicag.2020.106218 |
_version_ | 1783606905143296000 |
---|---|
author | Chowdhury, Trinath Baindara, Piyush Mandal, Santi M. |
author_facet | Chowdhury, Trinath Baindara, Piyush Mandal, Santi M. |
author_sort | Chowdhury, Trinath |
collection | PubMed |
description | INTRODUCTION: : The recent pandemic outbreak of SARS-CoV-2 has been associated with a lethal atypical pneumonia, making COVID-19 an urgent public health issue with an increasing rate of mortality and morbidity. There are currently no vaccines or therapeutics available for COVID-19, which is causing an urgent search for a new drug to combat the COVID-19 pandemic. The lipid membrane alternation efficiency of small antimicrobial lipopeptides enables them to block viral membrane fusion to the host cell. Lipopeptides could serve as potential antiviral agents, by interacting or competing with viral fusion proteins. METHODS: : This study screened seven different lipopeptides (tsushimycin, daptomycin, surfactin, bacillomycin, iturin, srfTE, and LPD-12) and docked them individually against the spike (S)-glycoprotein of SARS-CoV-2. RESULTS: : Based on the maximum docked score and minimum atomic contact energy, LPD-12 (–1137.38 kcal) was the appropriate molecule for proper binding with the S-glycoprotein of SARS-CoV-2 and thus significantly interrupted its affinity of binding with angiotensin-converting enzyme-2 (ACE2), which is the only receptor molecule found to be facilitating disease development. The results confirmed a strong binding affinity of LPD-12 with ACE2, with a binding free energy of –1621.62 kcal, which could also reciprocally prevent the binding of S-protein. CONCLUSTION: : It can be concluded that LPD-12 may act as a potential therapeutic drug, by reducing the entry of SARS-CoV-2 to the human cells via the ACE2 receptor and related infections. |
format | Online Article Text |
id | pubmed-7647407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd and International Society of Antimicrobial Chemotherapy. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76474072020-11-09 LPD-12: a promising lipopeptide to control COVID-19 Chowdhury, Trinath Baindara, Piyush Mandal, Santi M. Int J Antimicrob Agents Short Communication INTRODUCTION: : The recent pandemic outbreak of SARS-CoV-2 has been associated with a lethal atypical pneumonia, making COVID-19 an urgent public health issue with an increasing rate of mortality and morbidity. There are currently no vaccines or therapeutics available for COVID-19, which is causing an urgent search for a new drug to combat the COVID-19 pandemic. The lipid membrane alternation efficiency of small antimicrobial lipopeptides enables them to block viral membrane fusion to the host cell. Lipopeptides could serve as potential antiviral agents, by interacting or competing with viral fusion proteins. METHODS: : This study screened seven different lipopeptides (tsushimycin, daptomycin, surfactin, bacillomycin, iturin, srfTE, and LPD-12) and docked them individually against the spike (S)-glycoprotein of SARS-CoV-2. RESULTS: : Based on the maximum docked score and minimum atomic contact energy, LPD-12 (–1137.38 kcal) was the appropriate molecule for proper binding with the S-glycoprotein of SARS-CoV-2 and thus significantly interrupted its affinity of binding with angiotensin-converting enzyme-2 (ACE2), which is the only receptor molecule found to be facilitating disease development. The results confirmed a strong binding affinity of LPD-12 with ACE2, with a binding free energy of –1621.62 kcal, which could also reciprocally prevent the binding of S-protein. CONCLUSTION: : It can be concluded that LPD-12 may act as a potential therapeutic drug, by reducing the entry of SARS-CoV-2 to the human cells via the ACE2 receptor and related infections. Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021-01 2020-11-06 /pmc/articles/PMC7647407/ /pubmed/33166692 http://dx.doi.org/10.1016/j.ijantimicag.2020.106218 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Chowdhury, Trinath Baindara, Piyush Mandal, Santi M. LPD-12: a promising lipopeptide to control COVID-19 |
title | LPD-12: a promising lipopeptide to control COVID-19 |
title_full | LPD-12: a promising lipopeptide to control COVID-19 |
title_fullStr | LPD-12: a promising lipopeptide to control COVID-19 |
title_full_unstemmed | LPD-12: a promising lipopeptide to control COVID-19 |
title_short | LPD-12: a promising lipopeptide to control COVID-19 |
title_sort | lpd-12: a promising lipopeptide to control covid-19 |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647407/ https://www.ncbi.nlm.nih.gov/pubmed/33166692 http://dx.doi.org/10.1016/j.ijantimicag.2020.106218 |
work_keys_str_mv | AT chowdhurytrinath lpd12apromisinglipopeptidetocontrolcovid19 AT baindarapiyush lpd12apromisinglipopeptidetocontrolcovid19 AT mandalsantim lpd12apromisinglipopeptidetocontrolcovid19 |